We are live on ! Find out more
AVA

Atlas Venture Advisors Portfolio holdings

AUM $122M
1-Year Est. Return 26.28%
This Fund
S&P 500
This Quarter Est. Return
+63.27%
1 Year Est. Return
-26.28%
3 Year Est. Return
-22.79%
5 Year Est. Return
-46.44%
10 Year Est. Return
–
AUM
$594M
AUM Growth
+$203M
Cap. Flow
-$2.35M
Cap. Flow %
-0.4%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
2
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$1.37M
2
BCYC
Bicycle Therapeutics
BCYC
+$984K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 81.99%
2 Healthcare 14.12%
3 Communication Services 2.91%
4 Technology 0.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DKNG icon
1
DraftKings
DKNG
$11.4B
$487M 81.99%
8,284,008
– –
TBIO
2
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$52.2M 8.78%
3,833,120
-88,888
-2% -$1.37M
BCYC
3
Bicycle Therapeutics
BCYC
$270M
$24.9M 4.19%
1,306,965
-55,731
-4% -$984K
ROKU icon
4
Roku
ROKU
$21.1B
$10.9M 1.83%
57,707
– –
SNAP icon
5
Snap
SNAP
$7.32B
$6.41M 1.08%
245,559
– –
DDOG icon
6
Datadog
DDOG
$87.9B
$5.78M 0.97%
56,616
– –
LRMR icon
7
Larimar Therapeutics
LRMR
$416M
$4.43M 0.75%
292,184
– –
VRDN icon
8
Viridian Therapeutics
VRDN
$2.13B
$2.45M 0.41%
209,505
– –

Similar funds

RCWM
Red Crane Wealth Management San Francisco, California $122M AUM 14.77% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SO
Sierra Ocean Ripon, California $122M AUM 16.19% 1-Year Est. Return
MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
TCM
TT Capital Management Coto De Caza, California $121M AUM 1.94% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Atlas Venture Advisors's Q3 2020 Portfolio in Review

As of Q3 2020, Atlas Venture Advisors held 8 positions worth $594M, up 52% from $392M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2020: portfolio turnover was 0%. Atlas Venture Advisors opened no new positions and made no exits, leaving the 8-position portfolio largely intact.

By sector, the portfolio is most concentrated in Consumer Discretionary at 82% of assets, up from 70% a quarter earlier, followed by Healthcare and Communication Services.

  • Atlas Venture Advisors's biggest Q3 2020 reduction was Translate Bio, Inc. Common Stock, cutting an estimated $1.37M.
  • Atlas Venture Advisors's ten largest holdings make up 100% of its $594M portfolio in Q3 2020.
  • Atlas Venture Advisors opened 0 new positions and closed 0 in Q3 2020.
  • Atlas Venture Advisors's portfolio value rose 52% quarter-over-quarter to $594M.

Based on Atlas Venture Advisors's 13F filing for Q3 2020, filed 12 Nov 2020.